| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| West Nile virus | 24 | 2025 | 78 | 6.550 |
Why?
|
| West Nile Fever | 20 | 2025 | 68 | 4.700 |
Why?
|
| Viral Nonstructural Proteins | 8 | 2024 | 53 | 2.530 |
Why?
|
| Antibodies, Viral | 19 | 2025 | 306 | 2.500 |
Why?
|
| JC Virus | 8 | 2010 | 23 | 1.930 |
Why?
|
| Momordica charantia | 6 | 2019 | 17 | 1.860 |
Why?
|
| Blood-Brain Barrier | 7 | 2016 | 173 | 1.440 |
Why?
|
| Immunoassay | 6 | 2020 | 74 | 1.410 |
Why?
|
| Cytokines | 10 | 2023 | 678 | 1.210 |
Why?
|
| Polymerase Chain Reaction | 14 | 2019 | 455 | 1.190 |
Why?
|
| Brain | 12 | 2016 | 1472 | 1.170 |
Why?
|
| Virus Replication | 14 | 2024 | 318 | 1.170 |
Why?
|
| Dengue Virus | 6 | 2020 | 96 | 1.120 |
Why?
|
| Communicable Diseases, Emerging | 2 | 2024 | 14 | 0.980 |
Why?
|
| Humans | 80 | 2025 | 43102 | 0.920 |
Why?
|
| Interinstitutional Relations | 1 | 2025 | 51 | 0.900 |
Why?
|
| Genome, Viral | 4 | 2021 | 119 | 0.890 |
Why?
|
| Polyomavirus Infections | 3 | 2010 | 18 | 0.880 |
Why?
|
| Animals | 46 | 2025 | 16992 | 0.870 |
Why?
|
| Zoonoses | 1 | 2024 | 21 | 0.850 |
Why?
|
| Disease Models, Animal | 10 | 2025 | 1596 | 0.830 |
Why?
|
| Tight Junctions | 4 | 2016 | 27 | 0.810 |
Why?
|
| Microcephaly | 3 | 2020 | 21 | 0.790 |
Why?
|
| Cooperative Behavior | 1 | 2025 | 269 | 0.780 |
Why?
|
| Endothelial Cells | 4 | 2011 | 329 | 0.780 |
Why?
|
| Monocytes | 3 | 2023 | 277 | 0.770 |
Why?
|
| Mice, Inbred C57BL | 13 | 2019 | 1869 | 0.760 |
Why?
|
| Diagnostic Tests, Routine | 3 | 2019 | 51 | 0.750 |
Why?
|
| Cell Adhesion Molecules | 3 | 2014 | 83 | 0.730 |
Why?
|
| Cross Reactions | 2 | 2020 | 87 | 0.730 |
Why?
|
| Malaria, Falciparum | 2 | 2019 | 90 | 0.670 |
Why?
|
| Adipose Tissue | 3 | 2019 | 182 | 0.660 |
Why?
|
| Plasmodium falciparum | 2 | 2019 | 144 | 0.660 |
Why?
|
| Viral Envelope Proteins | 6 | 2025 | 91 | 0.660 |
Why?
|
| Microscopy | 3 | 2019 | 35 | 0.650 |
Why?
|
| Sequence Analysis, RNA | 4 | 2024 | 115 | 0.640 |
Why?
|
| Encephalitis Virus, Japanese | 1 | 2020 | 3 | 0.640 |
Why?
|
| Mutation | 4 | 2021 | 1177 | 0.640 |
Why?
|
| Flavivirus | 1 | 2020 | 16 | 0.630 |
Why?
|
| Biomedical Research | 1 | 2025 | 502 | 0.620 |
Why?
|
| Vero Cells | 7 | 2024 | 112 | 0.610 |
Why?
|
| Dengue | 4 | 2019 | 107 | 0.610 |
Why?
|
| Immunoglobulin M | 3 | 2016 | 86 | 0.610 |
Why?
|
| DNA, Viral | 12 | 2010 | 311 | 0.600 |
Why?
|
| Blood | 1 | 2019 | 37 | 0.600 |
Why?
|
| Antibodies, Neutralizing | 5 | 2023 | 127 | 0.590 |
Why?
|
| Hawaii | 7 | 2024 | 2011 | 0.580 |
Why?
|
| Cell Line | 13 | 2024 | 1410 | 0.570 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 83 | 0.570 |
Why?
|
| Microspheres | 3 | 2019 | 49 | 0.570 |
Why?
|
| Beverages | 2 | 2011 | 66 | 0.570 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 88 | 0.560 |
Why?
|
| Plant Extracts | 3 | 2011 | 302 | 0.560 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2020 | 24 | 0.560 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 2 | 2008 | 15 | 0.550 |
Why?
|
| Phylogeny | 13 | 2022 | 769 | 0.550 |
Why?
|
| Mice | 20 | 2025 | 6644 | 0.540 |
Why?
|
| B-Lymphocytes | 2 | 2010 | 189 | 0.540 |
Why?
|
| Neutralization Tests | 5 | 2021 | 57 | 0.530 |
Why?
|
| HIV-1 | 10 | 2021 | 755 | 0.520 |
Why?
|
| Gene Expression Profiling | 5 | 2019 | 704 | 0.520 |
Why?
|
| Lipid Metabolism | 2 | 2010 | 148 | 0.520 |
Why?
|
| Liver | 3 | 2011 | 511 | 0.510 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2014 | 760 | 0.500 |
Why?
|
| Membrane Proteins | 4 | 2014 | 561 | 0.500 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 8 | 2016 | 458 | 0.490 |
Why?
|
| Gene Expression Regulation | 7 | 2019 | 1070 | 0.480 |
Why?
|
| RNA, Messenger | 8 | 2019 | 1271 | 0.480 |
Why?
|
| Astrocytes | 3 | 2016 | 244 | 0.460 |
Why?
|
| Forkhead Transcription Factors | 2 | 2011 | 78 | 0.430 |
Why?
|
| Mothers | 1 | 2016 | 215 | 0.430 |
Why?
|
| Sulfonamides | 2 | 2010 | 91 | 0.410 |
Why?
|
| Leukocytes | 1 | 2014 | 80 | 0.410 |
Why?
|
| Neurons | 5 | 2019 | 1263 | 0.410 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2011 | 185 | 0.400 |
Why?
|
| Computational Biology | 1 | 2016 | 327 | 0.400 |
Why?
|
| Sensitivity and Specificity | 6 | 2019 | 611 | 0.400 |
Why?
|
| Dietary Fats | 2 | 2011 | 117 | 0.400 |
Why?
|
| Endoplasmic Reticulum | 1 | 2014 | 108 | 0.390 |
Why?
|
| Transcription Factors | 3 | 2010 | 735 | 0.390 |
Why?
|
| Neuroglia | 3 | 2008 | 133 | 0.390 |
Why?
|
| DNA Virus Infections | 3 | 2002 | 16 | 0.380 |
Why?
|
| RNA, Viral | 6 | 2010 | 321 | 0.380 |
Why?
|
| Interferon-alpha | 3 | 2013 | 43 | 0.380 |
Why?
|
| Acquired Immunodeficiency Syndrome | 4 | 2010 | 226 | 0.380 |
Why?
|
| Immunity | 1 | 2012 | 61 | 0.370 |
Why?
|
| MicroRNAs | 2 | 2019 | 518 | 0.370 |
Why?
|
| Gluconeogenesis | 1 | 2011 | 15 | 0.360 |
Why?
|
| Morinda | 1 | 2011 | 9 | 0.360 |
Why?
|
| Base Sequence | 11 | 2007 | 983 | 0.360 |
Why?
|
| Glycolysis | 1 | 2011 | 71 | 0.350 |
Why?
|
| Matrix Metalloproteinases | 2 | 2017 | 49 | 0.340 |
Why?
|
| Nitrobenzenes | 1 | 2010 | 19 | 0.340 |
Why?
|
| Encephalitis | 1 | 2011 | 43 | 0.340 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 2 | 2007 | 7 | 0.340 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2010 | 27 | 0.330 |
Why?
|
| Dinoprostone | 1 | 2010 | 64 | 0.330 |
Why?
|
| Cell Death | 2 | 2010 | 278 | 0.330 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 2 | 2017 | 25 | 0.330 |
Why?
|
| Adipogenesis | 1 | 2010 | 14 | 0.330 |
Why?
|
| Plant Preparations | 1 | 2010 | 24 | 0.320 |
Why?
|
| Adipocytes | 1 | 2010 | 60 | 0.310 |
Why?
|
| DNA Primers | 6 | 2013 | 294 | 0.310 |
Why?
|
| Neurodegenerative Diseases | 1 | 2011 | 141 | 0.310 |
Why?
|
| Inflammation Mediators | 1 | 2010 | 140 | 0.300 |
Why?
|
| Risperidone | 1 | 2008 | 5 | 0.290 |
Why?
|
| Viral Load | 3 | 2017 | 348 | 0.290 |
Why?
|
| Hepatitis, Viral, Human | 2 | 1999 | 12 | 0.290 |
Why?
|
| Apolipoproteins B | 2 | 2006 | 18 | 0.290 |
Why?
|
| Apolipoprotein B-100 | 1 | 2008 | 7 | 0.280 |
Why?
|
| Male | 27 | 2025 | 23409 | 0.280 |
Why?
|
| Immunoglobulin G | 4 | 2021 | 259 | 0.280 |
Why?
|
| Receptor, Insulin | 1 | 2008 | 25 | 0.280 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2012 | 95 | 0.280 |
Why?
|
| Oxidative Stress | 2 | 2011 | 1003 | 0.270 |
Why?
|
| Interferon-beta | 1 | 2007 | 9 | 0.270 |
Why?
|
| Child | 9 | 2025 | 3443 | 0.270 |
Why?
|
| Female | 24 | 2025 | 24698 | 0.260 |
Why?
|
| Sarcoma | 1 | 2007 | 11 | 0.260 |
Why?
|
| Tumor Virus Infections | 1 | 2007 | 22 | 0.260 |
Why?
|
| Carrier Proteins | 2 | 2010 | 321 | 0.260 |
Why?
|
| Evolution, Molecular | 3 | 2021 | 307 | 0.260 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2011 | 652 | 0.260 |
Why?
|
| Inflammation | 2 | 2023 | 758 | 0.260 |
Why?
|
| Lymphoma | 1 | 2007 | 41 | 0.260 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2020 | 117 | 0.250 |
Why?
|
| Capsid Proteins | 1 | 2007 | 76 | 0.250 |
Why?
|
| Infant | 6 | 2025 | 1175 | 0.250 |
Why?
|
| Testis | 2 | 2025 | 207 | 0.250 |
Why?
|
| HIV Protease Inhibitors | 1 | 2006 | 24 | 0.250 |
Why?
|
| Obesity | 2 | 2011 | 1151 | 0.240 |
Why?
|
| Selenium | 1 | 2008 | 155 | 0.240 |
Why?
|
| Hemagglutination Tests | 1 | 2006 | 4 | 0.240 |
Why?
|
| Torque teno virus | 2 | 2002 | 9 | 0.240 |
Why?
|
| Random Allocation | 3 | 2011 | 147 | 0.240 |
Why?
|
| Interferons | 1 | 2005 | 40 | 0.240 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 2 | 2005 | 26 | 0.240 |
Why?
|
| Cucurbitaceae | 1 | 2005 | 6 | 0.230 |
Why?
|
| Child, Preschool | 6 | 2025 | 1546 | 0.230 |
Why?
|
| Fetus | 2 | 2020 | 101 | 0.230 |
Why?
|
| Microsomes | 1 | 2005 | 55 | 0.230 |
Why?
|
| Polyomavirus | 1 | 2004 | 3 | 0.220 |
Why?
|
| Gene Expression Regulation, Viral | 3 | 2012 | 113 | 0.220 |
Why?
|
| Virology | 1 | 2004 | 8 | 0.220 |
Why?
|
| Dexamethasone | 1 | 2025 | 55 | 0.220 |
Why?
|
| Cameroon | 3 | 2019 | 35 | 0.220 |
Why?
|
| Peromyscus | 2 | 1994 | 11 | 0.220 |
Why?
|
| Culicidae | 1 | 2004 | 26 | 0.210 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2004 | 229 | 0.210 |
Why?
|
| Body Weight | 2 | 2019 | 429 | 0.210 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2006 | 163 | 0.210 |
Why?
|
| Pulmonary Fibrosis | 1 | 2024 | 38 | 0.200 |
Why?
|
| Research Personnel | 1 | 2025 | 206 | 0.200 |
Why?
|
| Prevalence | 6 | 2020 | 1612 | 0.200 |
Why?
|
| Viremia | 4 | 2017 | 44 | 0.200 |
Why?
|
| Liver Neoplasms | 1 | 2006 | 224 | 0.200 |
Why?
|
| Colon | 2 | 2019 | 120 | 0.200 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2003 | 16 | 0.200 |
Why?
|
| Vaccination | 2 | 2023 | 355 | 0.190 |
Why?
|
| HIV Infections | 5 | 2010 | 2586 | 0.190 |
Why?
|
| Proteins | 1 | 2005 | 382 | 0.190 |
Why?
|
| Public Policy | 1 | 2022 | 36 | 0.190 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2002 | 41 | 0.190 |
Why?
|
| Virulence | 3 | 2014 | 246 | 0.190 |
Why?
|
| Genetic Vectors | 4 | 2021 | 165 | 0.190 |
Why?
|
| Adult | 13 | 2020 | 13872 | 0.180 |
Why?
|
| DNA-Binding Proteins | 2 | 2005 | 561 | 0.180 |
Why?
|
| Epitopes | 1 | 2022 | 157 | 0.180 |
Why?
|
| Lipodystrophy | 1 | 2001 | 7 | 0.180 |
Why?
|
| Molecular Sequence Data | 9 | 2007 | 1542 | 0.180 |
Why?
|
| Infant, Newborn | 3 | 2020 | 972 | 0.180 |
Why?
|
| Sequence Analysis | 1 | 2021 | 26 | 0.170 |
Why?
|
| Membrane Glycoproteins | 1 | 2022 | 224 | 0.170 |
Why?
|
| Health Policy | 1 | 2022 | 184 | 0.170 |
Why?
|
| Antibodies, Monoclonal | 1 | 2022 | 306 | 0.170 |
Why?
|
| Hepatitis C | 2 | 1999 | 139 | 0.160 |
Why?
|
| Genomics | 1 | 2022 | 293 | 0.160 |
Why?
|
| Young Adult | 5 | 2019 | 5080 | 0.160 |
Why?
|
| Cell Line, Tumor | 5 | 2008 | 2676 | 0.160 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2019 | 161 | 0.160 |
Why?
|
| Reproducibility of Results | 2 | 2019 | 1081 | 0.160 |
Why?
|
| Blotting, Western | 4 | 2021 | 883 | 0.150 |
Why?
|
| Macrophages | 2 | 2019 | 529 | 0.150 |
Why?
|
| Fruit | 2 | 2011 | 178 | 0.150 |
Why?
|
| Adolescent | 7 | 2019 | 6081 | 0.150 |
Why?
|
| Panniculitis | 1 | 2019 | 2 | 0.150 |
Why?
|
| Algorithms | 1 | 2022 | 509 | 0.150 |
Why?
|
| Serologic Tests | 1 | 2019 | 45 | 0.150 |
Why?
|
| West Nile Virus Vaccines | 2 | 2009 | 5 | 0.150 |
Why?
|
| Cells, Cultured | 4 | 2019 | 1621 | 0.150 |
Why?
|
| Freeze Drying | 1 | 2019 | 29 | 0.150 |
Why?
|
| Adipokines | 1 | 2019 | 28 | 0.150 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2024 | 247 | 0.150 |
Why?
|
| Flaviviridae | 1 | 1998 | 4 | 0.150 |
Why?
|
| Dogs | 1 | 2019 | 204 | 0.150 |
Why?
|
| Ebolavirus | 1 | 2019 | 49 | 0.150 |
Why?
|
| Reactive Oxygen Species | 1 | 2001 | 532 | 0.140 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2010 | 384 | 0.140 |
Why?
|
| Genes, nef | 1 | 1998 | 5 | 0.140 |
Why?
|
| Phosphoproteins | 2 | 2010 | 206 | 0.140 |
Why?
|
| Gene Products, nef | 1 | 1998 | 19 | 0.140 |
Why?
|
| Blood Donors | 1 | 1998 | 20 | 0.140 |
Why?
|
| Doxycycline | 1 | 2017 | 32 | 0.130 |
Why?
|
| Pregnancy | 3 | 2020 | 1772 | 0.130 |
Why?
|
| Shrews | 2 | 2008 | 26 | 0.130 |
Why?
|
| Mice, Transgenic | 2 | 2023 | 665 | 0.130 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2019 | 213 | 0.130 |
Why?
|
| Blood Banks | 1 | 2016 | 10 | 0.130 |
Why?
|
| Guinea Pigs | 1 | 2017 | 143 | 0.130 |
Why?
|
| Toxoplasmosis | 1 | 2016 | 4 | 0.130 |
Why?
|
| Hotlines | 1 | 2017 | 16 | 0.130 |
Why?
|
| Plasmids | 2 | 2016 | 244 | 0.130 |
Why?
|
| Flow Cytometry | 2 | 2015 | 411 | 0.130 |
Why?
|
| Substance Abuse, Intravenous | 3 | 2007 | 129 | 0.130 |
Why?
|
| Genes, env | 2 | 1996 | 13 | 0.130 |
Why?
|
| Immunohistochemistry | 3 | 2015 | 934 | 0.130 |
Why?
|
| Rubella | 1 | 2016 | 16 | 0.130 |
Why?
|
| Saliva | 1 | 2017 | 119 | 0.120 |
Why?
|
| HIV Seropositivity | 1 | 1998 | 196 | 0.120 |
Why?
|
| Protein Transport | 2 | 2021 | 296 | 0.120 |
Why?
|
| Typhoid Fever | 1 | 2016 | 46 | 0.120 |
Why?
|
| Coronary Artery Disease | 1 | 2017 | 163 | 0.120 |
Why?
|
| United States | 3 | 2025 | 5205 | 0.120 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 3156 | 0.120 |
Why?
|
| Capillary Permeability | 1 | 2016 | 36 | 0.120 |
Why?
|
| Drug Resistance | 1 | 2016 | 96 | 0.120 |
Why?
|
| Sequence Analysis, Protein | 1 | 2016 | 52 | 0.120 |
Why?
|
| Malaria | 1 | 2016 | 90 | 0.120 |
Why?
|
| Blotting, Southern | 2 | 2007 | 68 | 0.110 |
Why?
|
| Cell Separation | 1 | 2015 | 94 | 0.110 |
Why?
|
| Cloning, Molecular | 1 | 2016 | 314 | 0.110 |
Why?
|
| Chemokines | 2 | 2013 | 96 | 0.110 |
Why?
|
| Gene Regulatory Networks | 1 | 2016 | 149 | 0.110 |
Why?
|
| Hantavirus Pulmonary Syndrome | 1 | 1994 | 3 | 0.110 |
Why?
|
| Sequence Analysis, DNA | 4 | 2007 | 515 | 0.110 |
Why?
|
| Viral Matrix Proteins | 1 | 2014 | 18 | 0.110 |
Why?
|
| Internationality | 1 | 2014 | 37 | 0.110 |
Why?
|
| Professional Competence | 1 | 2014 | 42 | 0.110 |
Why?
|
| Virus Internalization | 1 | 2014 | 36 | 0.110 |
Why?
|
| Receptors, Leptin | 1 | 2014 | 14 | 0.110 |
Why?
|
| Antibody Specificity | 1 | 2014 | 76 | 0.110 |
Why?
|
| Kinetics | 2 | 2012 | 695 | 0.110 |
Why?
|
| Defective Viruses | 2 | 2021 | 10 | 0.110 |
Why?
|
| Lentivirus | 2 | 2021 | 24 | 0.110 |
Why?
|
| Immunization | 1 | 2014 | 94 | 0.110 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2014 | 39 | 0.100 |
Why?
|
| Interleukin-1beta | 2 | 2013 | 75 | 0.100 |
Why?
|
| RNA, Transfer, Lys | 1 | 2013 | 2 | 0.100 |
Why?
|
| Reverse Transcription | 1 | 2013 | 23 | 0.100 |
Why?
|
| Middle Aged | 8 | 2019 | 12222 | 0.100 |
Why?
|
| Health Services Research | 1 | 2014 | 161 | 0.100 |
Why?
|
| Antigens, CD | 1 | 2014 | 127 | 0.100 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 2 | 2005 | 12 | 0.100 |
Why?
|
| Spleen | 1 | 2014 | 204 | 0.100 |
Why?
|
| Microscopy, Confocal | 1 | 2014 | 224 | 0.100 |
Why?
|
| Nucleoside-Triphosphatase | 2 | 2024 | 13 | 0.100 |
Why?
|
| Neurotoxins | 1 | 1993 | 57 | 0.100 |
Why?
|
| RNA Helicases | 2 | 2024 | 19 | 0.100 |
Why?
|
| DEAD-box RNA Helicases | 2 | 2024 | 25 | 0.100 |
Why?
|
| Cell Nucleus | 2 | 2024 | 383 | 0.100 |
Why?
|
| Serine Endopeptidases | 2 | 2024 | 48 | 0.100 |
Why?
|
| Complement System Proteins | 1 | 2012 | 25 | 0.090 |
Why?
|
| Antibody Formation | 1 | 2012 | 76 | 0.090 |
Why?
|
| HTLV-I Infections | 1 | 1992 | 33 | 0.090 |
Why?
|
| Amino Acid Sequence | 5 | 2004 | 1180 | 0.090 |
Why?
|
| Glucose Tolerance Test | 1 | 2012 | 75 | 0.090 |
Why?
|
| Glucose Intolerance | 1 | 2012 | 40 | 0.090 |
Why?
|
| Human T-lymphotropic virus 1 | 1 | 1992 | 35 | 0.090 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1992 | 50 | 0.090 |
Why?
|
| Nerve Tissue Proteins | 2 | 2014 | 386 | 0.090 |
Why?
|
| Cytoplasm | 2 | 2024 | 154 | 0.090 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2012 | 16 | 0.090 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2012 | 26 | 0.090 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 2853 | 0.090 |
Why?
|
| Disease Susceptibility | 1 | 2012 | 101 | 0.090 |
Why?
|
| Curriculum | 1 | 2014 | 318 | 0.090 |
Why?
|
| Cytoskeletal Proteins | 1 | 2013 | 116 | 0.090 |
Why?
|
| Hot Temperature | 1 | 2012 | 141 | 0.090 |
Why?
|
| Permeability | 1 | 2011 | 67 | 0.090 |
Why?
|
| Cytopathogenic Effect, Viral | 2 | 2008 | 14 | 0.090 |
Why?
|
| Species Specificity | 1 | 2012 | 286 | 0.090 |
Why?
|
| Immunity, Innate | 1 | 2013 | 171 | 0.090 |
Why?
|
| Aged | 4 | 2019 | 8214 | 0.090 |
Why?
|
| Hep G2 Cells | 1 | 2011 | 63 | 0.090 |
Why?
|
| Survival Analysis | 1 | 2012 | 368 | 0.090 |
Why?
|
| Aluminum | 3 | 1997 | 39 | 0.090 |
Why?
|
| Creutzfeldt-Jakob Syndrome | 3 | 1996 | 28 | 0.090 |
Why?
|
| Sirtuin 1 | 1 | 2011 | 34 | 0.090 |
Why?
|
| Microarray Analysis | 1 | 2011 | 64 | 0.090 |
Why?
|
| Gene Expression | 2 | 2012 | 701 | 0.090 |
Why?
|
| Pakistan | 2 | 2010 | 20 | 0.090 |
Why?
|
| Phytotherapy | 1 | 2011 | 75 | 0.080 |
Why?
|
| Catalase | 1 | 2011 | 110 | 0.080 |
Why?
|
| Glutathione Peroxidase | 1 | 2011 | 112 | 0.080 |
Why?
|
| Cell Transformation, Viral | 1 | 2010 | 24 | 0.080 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2010 | 25 | 0.080 |
Why?
|
| Superoxide Dismutase | 1 | 2011 | 158 | 0.080 |
Why?
|
| RNA Interference | 1 | 2011 | 247 | 0.080 |
Why?
|
| Demyelinating Diseases | 1 | 2010 | 14 | 0.080 |
Why?
|
| Lymphoid Tissue | 1 | 2010 | 19 | 0.080 |
Why?
|
| Lipogenesis | 1 | 2010 | 19 | 0.080 |
Why?
|
| Herpesvirus 4, Human | 1 | 2010 | 36 | 0.080 |
Why?
|
| Deoxyribonucleases | 1 | 2010 | 27 | 0.080 |
Why?
|
| Cyclooxygenase 2 | 1 | 2010 | 107 | 0.080 |
Why?
|
| Phenols | 1 | 2011 | 107 | 0.080 |
Why?
|
| Cell Movement | 1 | 2014 | 655 | 0.080 |
Why?
|
| Founder Effect | 1 | 2010 | 10 | 0.080 |
Why?
|
| Transduction, Genetic | 2 | 2008 | 21 | 0.080 |
Why?
|
| Dipeptides | 1 | 2009 | 31 | 0.080 |
Why?
|
| Neuroblastoma | 1 | 2010 | 136 | 0.080 |
Why?
|
| Microscopy, Fluorescence | 1 | 2010 | 256 | 0.080 |
Why?
|
| Protease Inhibitors | 1 | 2009 | 54 | 0.080 |
Why?
|
| Dietary Supplements | 1 | 2011 | 213 | 0.080 |
Why?
|
| Drug Users | 1 | 2010 | 52 | 0.080 |
Why?
|
| Hypoglycemic Agents | 1 | 2011 | 184 | 0.080 |
Why?
|
| Geese | 1 | 2008 | 4 | 0.070 |
Why?
|
| Bird Diseases | 1 | 2008 | 8 | 0.070 |
Why?
|
| Adenoviridae | 1 | 2008 | 62 | 0.070 |
Why?
|
| Sequence Alignment | 4 | 2010 | 272 | 0.070 |
Why?
|
| Phosphorylation | 1 | 2011 | 986 | 0.070 |
Why?
|
| Moloney murine leukemia virus | 1 | 2008 | 7 | 0.070 |
Why?
|
| Hepacivirus | 2 | 1999 | 74 | 0.070 |
Why?
|
| Transfection | 2 | 2008 | 532 | 0.070 |
Why?
|
| Apolipoprotein B-48 | 1 | 2008 | 7 | 0.070 |
Why?
|
| Cell Survival | 1 | 2011 | 945 | 0.070 |
Why?
|
| Recombination, Genetic | 1 | 2008 | 95 | 0.070 |
Why?
|
| Neuroprotective Agents | 1 | 2011 | 269 | 0.070 |
Why?
|
| Sexual Behavior | 2 | 2007 | 638 | 0.070 |
Why?
|
| Culture Media | 1 | 2008 | 96 | 0.070 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2021 | 186 | 0.070 |
Why?
|
| Kidney | 1 | 2010 | 372 | 0.070 |
Why?
|
| Vietnam | 2 | 1999 | 62 | 0.070 |
Why?
|
| Interferon Regulatory Factors | 1 | 2007 | 18 | 0.070 |
Why?
|
| Antioxidants | 1 | 2011 | 443 | 0.070 |
Why?
|
| Antigens, Viral, Tumor | 1 | 2007 | 6 | 0.070 |
Why?
|
| Hantavirus Infections | 1 | 2008 | 36 | 0.070 |
Why?
|
| Transcription, Genetic | 1 | 2010 | 592 | 0.070 |
Why?
|
| Serotonin Antagonists | 1 | 2007 | 22 | 0.060 |
Why?
|
| Cell Differentiation | 1 | 2010 | 638 | 0.060 |
Why?
|
| Communicable Disease Control | 1 | 2007 | 38 | 0.060 |
Why?
|
| Endothelium, Vascular | 1 | 2009 | 263 | 0.060 |
Why?
|
| Apolipoprotein C-III | 1 | 2006 | 7 | 0.060 |
Why?
|
| Apolipoprotein A-I | 1 | 2006 | 24 | 0.060 |
Why?
|
| Intestinal Mucosa | 1 | 2007 | 134 | 0.060 |
Why?
|
| Antiviral Agents | 1 | 2008 | 195 | 0.060 |
Why?
|
| Insulin Resistance | 1 | 2008 | 201 | 0.060 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 436 | 0.060 |
Why?
|
| Gene Dosage | 1 | 2006 | 75 | 0.060 |
Why?
|
| Escherichia coli | 1 | 2008 | 460 | 0.060 |
Why?
|
| Nicaragua | 1 | 2025 | 8 | 0.060 |
Why?
|
| Apolipoproteins E | 1 | 2006 | 138 | 0.060 |
Why?
|
| Oleic Acid | 1 | 2005 | 15 | 0.060 |
Why?
|
| Risk-Taking | 2 | 1999 | 457 | 0.060 |
Why?
|
| Dendrites | 2 | 1997 | 57 | 0.060 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 2004 | 8 | 0.060 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 2004 | 29 | 0.060 |
Why?
|
| Up-Regulation | 3 | 2019 | 536 | 0.060 |
Why?
|
| Cytosol | 1 | 2005 | 97 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2005 | 310 | 0.050 |
Why?
|
| Glioblastoma | 1 | 2005 | 74 | 0.050 |
Why?
|
| Databases, Nucleic Acid | 1 | 2004 | 30 | 0.050 |
Why?
|
| Anopheles | 1 | 2004 | 21 | 0.050 |
Why?
|
| Aedes | 1 | 2004 | 43 | 0.050 |
Why?
|
| Myeloid Cells | 1 | 2024 | 31 | 0.050 |
Why?
|
| Testosterone | 1 | 2025 | 211 | 0.050 |
Why?
|
| Immunization, Secondary | 1 | 2023 | 16 | 0.050 |
Why?
|
| Half-Life | 1 | 2023 | 63 | 0.050 |
Why?
|
| Bystander Effect | 1 | 2023 | 15 | 0.050 |
Why?
|
| Protein Structure, Tertiary | 2 | 2014 | 423 | 0.050 |
Why?
|
| Blood Cells | 1 | 2002 | 8 | 0.050 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2003 | 51 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2019 | 760 | 0.050 |
Why?
|
| Blood Transfusion | 1 | 2002 | 31 | 0.050 |
Why?
|
| Granulocytes | 1 | 2022 | 26 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2024 | 183 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2025 | 187 | 0.050 |
Why?
|
| Protein Structure, Secondary | 2 | 2012 | 182 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2004 | 279 | 0.050 |
Why?
|
| Acute Disease | 1 | 2003 | 155 | 0.050 |
Why?
|
| Bone Marrow Cells | 1 | 2002 | 79 | 0.050 |
Why?
|
| Antigens, CD19 | 1 | 2002 | 16 | 0.050 |
Why?
|
| Cell Membrane | 1 | 2024 | 403 | 0.050 |
Why?
|
| Ammonium Chloride | 1 | 2021 | 4 | 0.050 |
Why?
|
| Convalescence | 1 | 2021 | 7 | 0.050 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2021 | 20 | 0.050 |
Why?
|
| Emigration and Immigration | 1 | 2002 | 85 | 0.040 |
Why?
|
| Genetics, Population | 1 | 2002 | 121 | 0.040 |
Why?
|
| Genes, Reporter | 1 | 2021 | 148 | 0.040 |
Why?
|
| Virus Integration | 1 | 2002 | 65 | 0.040 |
Why?
|
| Point Mutation | 1 | 2021 | 98 | 0.040 |
Why?
|
| Endoplasmic Reticulum, Rough | 1 | 2021 | 3 | 0.040 |
Why?
|
| Disease Progression | 1 | 2024 | 667 | 0.040 |
Why?
|
| Genes, Viral | 2 | 1998 | 61 | 0.040 |
Why?
|
| Pregnancy Trimesters | 1 | 2020 | 15 | 0.040 |
Why?
|
| Apoptosis | 1 | 2008 | 1568 | 0.040 |
Why?
|
| Recombinant Proteins | 2 | 2019 | 518 | 0.040 |
Why?
|
| Age of Onset | 1 | 2020 | 114 | 0.040 |
Why?
|
| Phenotype | 1 | 2022 | 780 | 0.040 |
Why?
|
| Liberia | 1 | 2019 | 13 | 0.040 |
Why?
|
| Incidence | 1 | 2002 | 1078 | 0.040 |
Why?
|
| Seroepidemiologic Studies | 1 | 2019 | 74 | 0.040 |
Why?
|
| Hepatitis Viruses | 1 | 1999 | 3 | 0.040 |
Why?
|
| Vaccines, Subunit | 2 | 2009 | 34 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2005 | 968 | 0.040 |
Why?
|
| DNA Viruses | 1 | 1999 | 14 | 0.040 |
Why?
|
| High-Throughput Screening Assays | 1 | 2019 | 74 | 0.040 |
Why?
|
| Alanine Transaminase | 1 | 1998 | 27 | 0.040 |
Why?
|
| Sexually Transmitted Diseases, Viral | 1 | 1998 | 12 | 0.040 |
Why?
|
| Receptors, CCR5 | 1 | 1999 | 64 | 0.040 |
Why?
|
| Sequence Deletion | 1 | 1999 | 93 | 0.040 |
Why?
|
| Risk Factors | 1 | 2007 | 3994 | 0.040 |
Why?
|
| DNA, Complementary | 1 | 1998 | 196 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2022 | 1759 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2017 | 14 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 1999 | 201 | 0.030 |
Why?
|
| Elastin | 1 | 2017 | 40 | 0.030 |
Why?
|
| Mitochondria | 1 | 2001 | 523 | 0.030 |
Why?
|
| nef Gene Products, Human Immunodeficiency Virus | 1 | 1998 | 59 | 0.030 |
Why?
|
| Optic Nerve | 2 | 1995 | 30 | 0.030 |
Why?
|
| China | 1 | 1998 | 229 | 0.030 |
Why?
|
| Pacific Ocean | 1 | 2017 | 13 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2017 | 317 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2019 | 456 | 0.030 |
Why?
|
| Inclusion Bodies | 1 | 1996 | 34 | 0.030 |
Why?
|
| Insecticide-Treated Bednets | 1 | 2016 | 8 | 0.030 |
Why?
|
| Echocardiography | 1 | 2017 | 167 | 0.030 |
Why?
|
| Cats | 1 | 2016 | 82 | 0.030 |
Why?
|
| Health Facilities | 1 | 2016 | 32 | 0.030 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 1996 | 58 | 0.030 |
Why?
|
| Interleukin-1 | 1 | 1996 | 39 | 0.030 |
Why?
|
| HIV Seroprevalence | 1 | 1996 | 11 | 0.030 |
Why?
|
| Brain Stem | 1 | 1996 | 52 | 0.030 |
Why?
|
| Sex Factors | 1 | 2020 | 1028 | 0.030 |
Why?
|
| Point-of-Care Systems | 1 | 2016 | 35 | 0.030 |
Why?
|
| Thailand | 1 | 1996 | 51 | 0.030 |
Why?
|
| Fever | 1 | 2016 | 62 | 0.030 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 1996 | 75 | 0.030 |
Why?
|
| Temperature | 1 | 2017 | 313 | 0.030 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2016 | 40 | 0.030 |
Why?
|
| Antimalarials | 1 | 2016 | 64 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 375 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2008 | 267 | 0.030 |
Why?
|
| Spinal Cord | 1 | 1996 | 114 | 0.030 |
Why?
|
| Occupational Diseases | 1 | 1996 | 53 | 0.030 |
Why?
|
| Genetic Variation | 2 | 2002 | 430 | 0.030 |
Why?
|
| Encephalitis, Viral | 1 | 1995 | 6 | 0.030 |
Why?
|
| Research | 1 | 2017 | 181 | 0.030 |
Why?
|
| Placenta | 1 | 2016 | 117 | 0.030 |
Why?
|
| Human T-lymphotropic virus 2 | 1 | 1995 | 1 | 0.030 |
Why?
|
| Indians, South American | 1 | 1995 | 9 | 0.030 |
Why?
|
| Membranes | 1 | 2014 | 18 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2014 | 135 | 0.030 |
Why?
|
| Protein Precursors | 1 | 2014 | 59 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2014 | 91 | 0.030 |
Why?
|
| RNA, Complementary | 1 | 2013 | 10 | 0.030 |
Why?
|
| Bunyaviridae Infections | 1 | 1993 | 7 | 0.030 |
Why?
|
| Hemorrhagic Fever with Renal Syndrome | 1 | 1993 | 21 | 0.030 |
Why?
|
| Nucleotides | 1 | 1993 | 37 | 0.030 |
Why?
|
| Southwestern United States | 1 | 1993 | 47 | 0.030 |
Why?
|
| Leukemia, Radiation-Induced | 1 | 1993 | 1 | 0.030 |
Why?
|
| Leukemia, Lymphoid | 1 | 1993 | 2 | 0.030 |
Why?
|
| Thymidine | 1 | 1993 | 15 | 0.030 |
Why?
|
| Plasticizers | 1 | 1993 | 7 | 0.030 |
Why?
|
| Tritium | 1 | 1993 | 46 | 0.030 |
Why?
|
| Hippocampus | 1 | 1997 | 594 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2017 | 1600 | 0.020 |
Why?
|
| Fluorouracil | 1 | 1993 | 47 | 0.020 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1993 | 64 | 0.020 |
Why?
|
| Aluminum Compounds | 1 | 1993 | 10 | 0.020 |
Why?
|
| Caspase 1 | 1 | 2013 | 16 | 0.020 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2013 | 11 | 0.020 |
Why?
|
| Antibody Affinity | 1 | 2012 | 21 | 0.020 |
Why?
|
| Homosexuality, Male | 1 | 1998 | 486 | 0.020 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2012 | 41 | 0.020 |
Why?
|
| Phosphates | 1 | 1993 | 54 | 0.020 |
Why?
|
| Amino Acids | 1 | 1993 | 148 | 0.020 |
Why?
|
| Protein Stability | 1 | 2012 | 48 | 0.020 |
Why?
|
| Melanesia | 1 | 1992 | 23 | 0.020 |
Why?
|
| Papua New Guinea | 1 | 1992 | 21 | 0.020 |
Why?
|
| Templates, Genetic | 1 | 1992 | 23 | 0.020 |
Why?
|
| Base Composition | 1 | 1992 | 26 | 0.020 |
Why?
|
| Cell Division | 1 | 1993 | 311 | 0.020 |
Why?
|
| DNA Replication | 1 | 1993 | 148 | 0.020 |
Why?
|
| Motor Neurons | 1 | 1993 | 90 | 0.020 |
Why?
|
| Nerve Degeneration | 1 | 1993 | 111 | 0.020 |
Why?
|
| DNA, Single-Stranded | 1 | 1992 | 40 | 0.020 |
Why?
|
| Glioma | 1 | 1993 | 96 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 1993 | 508 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 2013 | 132 | 0.020 |
Why?
|
| California | 1 | 1993 | 548 | 0.020 |
Why?
|
| Taste | 1 | 2011 | 45 | 0.020 |
Why?
|
| Pacific Islands | 2 | 2002 | 123 | 0.020 |
Why?
|
| Vegetables | 1 | 2011 | 147 | 0.020 |
Why?
|
| Transients and Migrants | 1 | 2010 | 42 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2013 | 1035 | 0.020 |
Why?
|
| Vaccines, Synthetic | 1 | 2009 | 80 | 0.020 |
Why?
|
| Protein Binding | 1 | 2012 | 1082 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2011 | 389 | 0.020 |
Why?
|
| Macaca mulatta | 1 | 2009 | 139 | 0.020 |
Why?
|
| Genetic Techniques | 1 | 2008 | 14 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2009 | 152 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2010 | 246 | 0.020 |
Why?
|
| Virus Assembly | 1 | 2008 | 44 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2008 | 88 | 0.020 |
Why?
|
| Disease Reservoirs | 1 | 2008 | 25 | 0.020 |
Why?
|
| Drosophila melanogaster | 1 | 2009 | 193 | 0.020 |
Why?
|
| Myelin Sheath | 2 | 1996 | 46 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2006 | 183 | 0.010 |
Why?
|
| Rats | 1 | 1993 | 3735 | 0.010 |
Why?
|
| Diet | 1 | 2011 | 826 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2006 | 209 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2005 | 207 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2006 | 259 | 0.010 |
Why?
|
| Lung | 1 | 2008 | 492 | 0.010 |
Why?
|
| Microscopy, Electron | 2 | 1996 | 210 | 0.010 |
Why?
|
| Rabbits | 2 | 1996 | 278 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2009 | 1455 | 0.010 |
Why?
|
| Genotype | 1 | 2002 | 800 | 0.010 |
Why?
|
| Asia | 1 | 1999 | 98 | 0.010 |
Why?
|
| Heterozygote | 1 | 1999 | 110 | 0.010 |
Why?
|
| Gene Frequency | 1 | 1999 | 206 | 0.010 |
Why?
|
| Alleles | 1 | 1999 | 352 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1996 | 150 | 0.010 |
Why?
|
| Biological Transport | 1 | 1997 | 204 | 0.010 |
Why?
|
| HTLV-II Infections | 1 | 1995 | 6 | 0.010 |
Why?
|
| Gene Products, tax | 1 | 1995 | 4 | 0.010 |
Why?
|
| Genetic Heterogeneity | 1 | 1995 | 11 | 0.010 |
Why?
|
| Serotyping | 1 | 1995 | 37 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1995 | 36 | 0.010 |
Why?
|
| Colombia | 1 | 1995 | 31 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 1999 | 734 | 0.010 |
Why?
|
| Antigens, Viral | 1 | 1995 | 48 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 1995 | 95 | 0.010 |
Why?
|
| RNA | 1 | 1997 | 266 | 0.010 |
Why?
|
| Nucleic Acid Conformation | 1 | 1995 | 154 | 0.010 |
Why?
|
| Gamma Rays | 1 | 1993 | 27 | 0.010 |
Why?
|
| Mice, Inbred ICR | 1 | 1993 | 44 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 1993 | 129 | 0.010 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 1993 | 97 | 0.010 |
Why?
|
| Drug Stability | 1 | 1993 | 129 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 1993 | 114 | 0.010 |
Why?
|
| Liposomes | 1 | 1993 | 132 | 0.010 |
Why?
|
| Time Factors | 1 | 1996 | 1857 | 0.010 |
Why?
|
| Drug Carriers | 1 | 1993 | 174 | 0.010 |
Why?
|